Healthcare Industry News: radiation therapy
News Release - December 19, 2013
University of California San Diego and John Muir Medical Center Initiate Treating Patients for Colon and Lung Cancer Utilizing IsoRay's Cesium-131 Seeded MeshRICHLAND, WA--(Healthcare Sales & Marketing Network) - IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has two new medical centers using its sutured seeds in mesh to treat colon and lung cancers.
IsoRay CEO Dwight Babcock noted, "We are extremely encouraged by the number of new facilities taking notice of the successes achieved by other major cancer centers when Cesium-131 is made available to their patients. We are excited to have the University of California and John Muir Medical Center as our newest thought leaders utilizing Cesium-131 products for newly diagnosed and recurrent cancers where other treatments have previously failed. Currently all of our studies in multiple medical centers are performing well with positive results in treating brain cancers, meningioma tumors, pelvic wall, lung cancer, colon cancer, gynecologic cancer and prostate cancer with our Cesium-131 product line. We are making a difference in thousands of lives by providing new ideas and solutions in the battle against cancer and we believe Cesium-131 is the isotope of the future."
IsoRay's Cesium-131 sutured seeds, stranded mesh and the GliaSiteŽ radiation therapy system each give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of brain tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy brain and lung tissue as well as critical structures compared to other alternative treatments. IsoRay's cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.
IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form for brachytherapy in approximately 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSiteŽ and Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter@isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed and its various delivery formats, the advantages of the GliasiteŽ delivery system, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of GliaSiteŽ or Cesium-131 will increase or continue, whether future studies of treatment of various cancers using our products will have favorable results, whether the medical schools referred to will continue to use our products, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, patient results achieved with Cesium-131 or the GliasiteŽ delivery system, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use Cesium-131 in its various forms as well as our other products in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.